


PHARMACEUTICAL 2017

LANDEC CORP \CA\ Rank 46 of 313







PHARMACEUTICAL 2017



LANDEC CORP \CA\ Rank 46 of 313



The relative strengths and weaknesses of LANDEC CORP \CA\ are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of LANDEC CORP \CA\ compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 854% points. The greatest weakness of LANDEC CORP \CA\ is the variable Other Expenses, reducing the Economic Capital Ratio by 683% points.

The company's Economic Capital Ratio, given in the ranking table, is 79%, being 495% points above the market average of -417%.

| Input Variable | Value in 1000 USD |
|---|-------------------|
| Assets, Current | 86,478 |
| Cost of Goods Sold | 0 |
| Intangible Assets | 49,620 |
| Liabilities, Current | 56,516 |
| Liabilities, Non-Current | 46,614 |
| Other Assets | 86,492 |
| Other Compr. Net Income | -193 |
| Other Expenses | 498,725 |
| Other Liabilities | 27,990 |
| Other Net Income | 2,921 |
| Property and Equipment | 120,880 |
| Research and Development | 7,228 |
| Revenues | 541,099 |
| Selling, General and Administrative Expense | 49,515 |

| Output Variable | Value in 1000 USD |
|--------------------------|-------------------|
| Assets | 343,470 |
| Liabilities | 131,120 |
| Expenses | 555,468 |
| Stockholders Equity | 212,350 |
| Net Income | -11,448 |
| Comprehensive Net Income | -11,544 |
| Economic Capital Ratio | 79% |